Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T18:48:01.387Z.
Calculation as of: 2026-10-06T18:48:01.387Z.
Quote observation: 2026-10-06T18:45:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 970d877bc7db717cbed859036c212f4e9de57f4ce891843b12d0c27006da4837
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Seaport Therapeutics, Inc. Common Stock
Market Cap
$933.65M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$931.68M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$935.68M
Operating Cash Flow Yield
N/A
TTM Avg
16.88%
3Y Avg
16.91%
5Y Avg
16.91%
Market Cap
$912.68M
Operating Cash Flow Yield
7.87%
TTM Avg
8.82%
3Y Avg
7.69%
5Y Avg
7.20%
Market Cap
$965.04M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$898.60M
Operating Cash Flow Yield
10.78%
TTM Avg
11.28%
3Y Avg
6.74%
5Y Avg
6.11%
Market Cap
$978.86M
Operating Cash Flow Yield
19.17%
TTM Avg
14.96%
3Y Avg
15.37%
5Y Avg
11.65%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seaport Therapeutics, Inc. Common Stock (SPTX) | $933.65M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $932.25M | N/A | N/A | N/A | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $931.68M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $935.68M | N/A | 16.88% | 16.91% | 16.91% |
| Savara Inc. (SVRA)vs › | $953.94M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $912.68M | 7.87% | 8.82% | 7.69% | 7.20% |
| Aktis Oncology, Inc. (AKTS)vs › | $965.04M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $898.60M | 10.78% | 11.28% | 6.74% | 6.11% |
| Pacira BioSciences, Inc. (PCRX)vs › | $978.86M | 19.17% | 14.96% | 15.37% | 11.65% |
| Arbutus Biopharma Corp (ABUS)vs › | $882.99M | N/A | 8.30% | 22.27% | 22.27% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
